Failure of pre-exposure prophylaxis with daily tenofovir/emtricitabine and the scenario of delayed HIV seroconversion
- Resource Type
- Authors
- Grace Lui; Denise P. Chan; Shui Shan Lee; Krystal C.K. Lee; Tsz-Ho Kwan; Ngai Sze Wong; Peter L. Anderson; Teddy Tai Ning Lam
- Source
- International Journal of Infectious Diseases, Vol 94, Iss, Pp 41-43 (2020)
- Subject
- 0301 basic medicine
Microbiology (medical)
2019-20 coronavirus outbreak
HIV seroconversion
Tenofovir
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
030106 microbiology
Human immunodeficiency virus (HIV)
medicine.disease_cause
Emtricitabine
lcsh:Infectious and parasitic diseases
03 medical and health sciences
Pre-exposure prophylaxis
0302 clinical medicine
medicine
lcsh:RC109-216
030212 general & internal medicine
Seroconversion
business.industry
virus diseases
General Medicine
Virology
Antiretroviral
Infectious Diseases
business
PrEP failure
medicine.drug
- Language
- ISSN
- 1201-9712
Failure of pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate and emtricitabine may occur despite perfect adherence, although this is uncommon. Failure results in breakthrough HIV infection. Delayed seroconversion associated with antiretroviral use may complicate the picture, causing uncertainties in interpreting adherence patterns for establishing the true cause of PrEP failure.